摘要
目的探讨孟鲁司特联合酮替酚对咳嗽变异性哮喘(CVA)患者金属蛋白酶(MMP)-2、9水平的影响及疗效观察。方法将90例CVA患者随机分为观察组和对照组。两组予以舒喘灵气雾剂治疗,咳嗽消失后停药。观察组加用孟鲁司特咀嚼片(10 mg/次,1次/d,口服)联合酮替酚片(1 mg/次,2次/d,口服)治疗,对照组予以单纯孟鲁司特咀嚼片治疗,剂量与用法同观察组,两组疗程8周。结果治疗8周后,两组血清MMP-2和MMP-9均明显下降(P<0.05或P<0.01),且观察组下降较对照组更明显(P<0.05);观察组总有效率较对照组更明显(χ2=4.41,P<0.05)。对照组发生不良反应3例,观察组6例,症状均较轻微,两组比较差异不明显(χ2=0.49,P>0.05)。随访1年,观察组复发率低于对照组(χ2=6.33,P<0.05)。结论孟鲁司特联合酮替酚治疗CVA的效果及安全性均较好,且能降低复发率,作用可能与降低血清MMP-2和MMP-9水平密切相关。
Objective To discuss curative effect and influence on plasma of MMP-2 and MMP-9 levels of Montelukast combined with ketotifen on cough variant asthma（CVA）. Methods A total of 90 cases of patients with CVA were divided into observation group and control group by numeration table at random. The patients in two groups were given Salbutamol Aerosol treatment until the disappearing of cough. The patients in observation group were additionally given Montelukast Dulcets（10 mg per time, once a day, through the mouth） combined with ketotifen tablets（1 mg per time, twice a day, through the mouth）, while the patients in control group were given the pure Montelukast Dulcets with the same dose and method as those in observation group, for 8 weeks as the course of treatment. Results After 8weeks＇ treatment, the plasma MMP-2 and MMP-9 levels descended significantly（P〈0.05 or P〈0.01）,and the rangeabilities of budesonide group were more significantly obviously than those in control group（P〈0.05）, and the total efficiency of patients in observation group was much higher than that in control group（χ^2=4.41,P〈0.05）, 3 and 6 cases of untoward effect appeared in control group and observation group respectively, with light symptom and the untoward effect occurrence rates of patients in two groups appeared no obvious differences after comparison（χ^2=0.49,P〉0.05）.According to the one-year following-up after the withdrawal of drugs, reoccurrence rate of patients in observation group was much lower than that in control group（χ^2=6.33,P〈0.05）. Conclusion Montelukast combined with Ketotifen has favorable clinical curative effect on CVA with high security,and can reduce the reoccurrence rate. May its mechanism relates to down-regulating MMP-2 and MMP-9.
出处
《中国现代医生》
2015年第4期70-72,共3页
China Modern Doctor
基金
浙江省医学会临床科研基金(2011ZYC-A50)
